Lidak has just released their 4q info:
Lidak Pharmaceuticals (LDAKA) Q4 full results
LA JOLLA, Calif., Dec. 26 (Reuter) -
LIDAK PHARMACEUTICALS
SUMMARY FINANCIAL INFORMATION
Statement of operations data: Years ended September 30,
1996 1995
Revenues $4,158,038 $884,589
Net loss (6,130,241) (10,173,001)
Net loss per share (0.19) (0.35)
Weighted average shares outstanding
32,072,944 29,338,418
Balance sheet data: Cash, cash equivalents and
short term investments 20,374,010 10,035,727
Working capital 13,759,577 8,567,966
Total assets 22,846,879 10,954,043
Total liabilities 7,778,760 1,705,443
Stockholders' equity 15,068,119 9,248,600
SELECTED QUARTERLY FINANCIAL INFORMATION
Year ended September 30, 1996
First Second Third Fourth
REVENUES: License fees/Contract
research -- $3,000,000 -- $16,800
Federal SBIR grants
6,500 11,332 25,168 15,000
Interest and other
190,035 279,336 306,050 307,817
Total revenues
196,535 3,290,668 331,218 339,617
EXPENSES: Research and
development 1,441,423 1,115,346 920,336 1,099,321
General and
administrative
650,143 901,709 636,654 556,660
Interest 175,374 3,231,685 2,672,114 2,117,540
Total expenses
2,266,940 3,231,685 2,672,114 2,117,540
NET INCOME (LOSS)
(2,070,405) 58,983 (2,340,896) (1,777,923)
NET INCOME (LOSS) PER SHARE
(0.07) 0.00 (0.07) (0.05)
Rtr 15:54 12-26-96 (Eastern Standard Time)
|
